Rosen Law Firm Encourages Altimmune, Inc. Investors to Act Before July Deadline in Class Action

New York-based Rosen Law Firm, recognized for defending global investor rights, is issuing a reminder to Altimmune, Inc. ALT investors to seek legal counsel ahead of a critical deadline in a securities class action lawsuit. The firm is calling attention to those who acquired Altimmune securities between December 1, 2023, and April 26, 2024—known as the Class Period. The lead plaintiff deadline is set for July 5, 2024, and approaching fast.

Background on Altimmune, Inc.

Altimmune, Inc. ALT, a clinical-stage biopharmaceutical entity headquartered in Gaithersburg, Maryland, specializes in developing intranasal vaccines and therapies geared towards immunomodulation and liver diseases. With a mission to address medical needs through innovative treatments, Altimmune is at the forefront of vaccine research and liver health solutions.

Details of the Securities Class Action

The legal action against Altimmune Inc. alleges that the company violated federal securities laws by issuing materially false and/or misleading information, and/or failing to disclose pertinent details related to its business operations and prospects. Investors who purchased Altimmune securities during the Class Period and sustained losses due to this alleged misinformation are encouraged by Rosen Law Firm to initiate steps towards securing legal representation before the July deadline.

Instructions for Affected Investors

Shareholders of Altimmune who wish to serve as the lead plaintiff in the class action must act timely and file appropriate motions with the court by the stated deadline. The position is not mandatory for individual class members who wish to participate in any recovery. Rosen Law Firm is prepared to provide guidance to Altimmune investors on the necessary legal proceedings and the implications of the case.

Rosen, Altimmune, Deadline